BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Research Notes

LifeVantage: A $58 Million Buyback Program and a Quarter That Lost Money

Moe Alsumidaie by Moe Alsumidaie
November 20, 2026
in Research Notes
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

LifeVantage spent most of the last decade building its reputation on a single idea: that a supplement called Protandim could slow the cellular wear-and-tear that comes with aging. The pitch worked well enough to push annual revenue past $220 million by 2021. Then the company chased the weight-loss boom with a product called the MindBody GLP-1 System, revenue jumped double digits in fiscal 2025, and the stock briefly looked like it had found a second act. The November 9 quarterly filing ended that story, at least for now.

What matters here

The math shows a business that swung from profit to loss in a single quarter, driven almost entirely by one product line losing momentum. The mood, measured by today’s price, sits well below the company’s own decade-average valuation. The open question is whether the LoveBiome acquisition and a restructured calendar year give management enough new material to reverse a customer count that is still falling.

Two numbers that should not coexist

LifeVantage’s board approved a $60 million share repurchase program, of which $58.5 million remains unspent as of September 30, 2026. In the same quarter, the company posted a net loss. A company confident enough in its own future to authorize nearly its entire annual revenue in buybacks did not spend a dollar of it, and simultaneously slipped into the red. Those two facts sit in the same filing, and the tension between them is the story.

The 10-Q filed November 9, 2026, covering the quarter ended September 30, 2026, shows revenue of $37.1 million, down roughly a fifth from the same quarter a year earlier. To feel that drop at kitchen-table scale: imagine a small business that collected about $48,000 last autumn collecting only $37,000 this autumn, with fixed costs largely unchanged. The net result was a loss where a solid profit had existed twelve months before, a sign that the cost base did not shrink as fast as the revenue did.

BullScope TerminalLFVN was the article. The engine is the product.Same yardsticks, any ticker: filed financials in, math-vs-mood out. Nothing here is advice; it is the evidence, organized.Run another company →

What broke, and what was bought to fix it

Management’s own language in the November 9 earnings release points to two culprits: fewer active customer accounts and sharply lower sales of the MindBody GLP-1 System. The GLP-1 product was the engine of last year’s revenue surge, per our data computed from the fiscal 2026 10-K. When that engine stalled, there was nothing else large enough to hold the line.

The partial offset came from LoveBiome, a gut-health product line LifeVantage acquired in October 2025. The dossier confirms it contributed some sales this quarter, but the filing does not break out a specific figure, so we cannot say how much. What the geography does tell us: Americas revenue fell sharply to $29 million, and Asia-Pacific and Europe fell by a similar proportion to $8.2 million. The decline was not a regional story. It was company-wide.

For a saver trying to read the business, the customer-count decline is the more durable concern. Revenue from a product launch can bounce; a shrinking base of active accounts is a structural problem that takes time and marketing spend to reverse.

The calendar-year pivot

Buried in the same filing is a procedural change that matters more than it sounds. On September 29, 2026, LifeVantage’s board approved switching the company’s fiscal year end from June 30 to December 31. The stated reason is to align reporting with the calendar year, which is standard practice and makes comparisons with peers easier. The practical effect is a transition period that will produce a short, stub fiscal year, making the next several quarters harder to compare cleanly against history. Investors reading the next few filings will need to track which period is which.

Reading the numbers

  • $37.1 million quarterly revenue (Q1 FY2027, ended September 30, 2026). What it is: total sales for the quarter. What it means here: the company is running at an annualized pace well below the $183 million our data shows for full fiscal 2026, suggesting the revenue decline accelerated into the new fiscal year. Everyday example: a shop that did $183,000 last year is now on pace closer to $148,000, if this quarter’s rate holds.
  • 22% revenue decline year-over-year. What it is: the percentage drop from $47.6 million to $37.1 million. What it means here: roughly one dollar in five of last year’s sales did not come back. Everyday example: a household that earned $4,760 in freelance work last autumn earned about $3,710 this autumn doing the same work.
  • Net loss of $0.2 million versus net income of $2.2 million a year ago. What it is: the bottom line, after all costs. What it means here: the business crossed from profitable to unprofitable in twelve months, a swing of about $2.4 million on roughly $10 million less revenue. That math says costs did not fall nearly as fast as sales.
  • $58.5 million remaining under the $60 million buyback program. What it is: authorized but unspent capacity to repurchase shares. What it means here: the board approved the program but did not deploy it this quarter, which may reflect caution about cash while revenue is falling. A buyback spends real cash; not using it preserves flexibility.
  • P/E of 12.0 versus a decade median of 15.6 (our data). What it is: the price-to-earnings multiple, meaning the price tag the market puts on each dollar of annual profit. What it means here: the stock is priced at a discount to its own history. Everyday example: a business that historically sold for $15.60 per dollar of annual profit is selling today for $12.00 per dollar, about 23% cheaper than its own norm.

Sources

  • 10-Q for quarter ended September 30, 2026 (SEC EDGAR)
  • 10-K for fiscal year ended June 30, 2026 (SEC EDGAR)
  • 10-Q for quarter ended September 30, 2025 (SEC EDGAR)
  • LifeVantage Q1 FY2027 earnings release (GlobeNewswire, November 9, 2026)
  • LifeVantage Q1 FY2027 results summary (StockTitan)
BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read LFVN’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

AnaptysBio: The Royalty Company That Used to Be a Drug Company

by Moe Alsumidaie
November 19, 2026
0

For most of its life, AnaptysBio was a bet on science. It discovered drug candidates, ran trials, and hoped one would survive long enough to reach patients. Then,...

Read moreDetails

Vafseo Is Growing. Auryxia Is Collapsing. Both Are True at Once.

by Moe Alsumidaie
November 19, 2026
0

Four years ago, Akebia Therapeutics was a company the FDA had just rejected, laying off nearly half its staff and watching its lead partner walk away. Today, that...

Read moreDetails

Vaxart: Government Revenue Falls 85%, and the Clock Starts Ticking

by Moe Alsumidaie
November 19, 2026
0

A year ago, Vaxart looked like a company with a government backstop. BARDA, the federal agency that funds pandemic preparedness, had committed hundreds of millions of dollars to...

Read moreDetails

Keros Therapeutics: A Quarter That Earned Its Keep, and the Longer Bet Behind It

by Moe Alsumidaie
November 18, 2026
0

Eighteen months ago, Keros cut nearly half its staff and buried its most advanced drug. Today, the same company is posting net income, sitting on a cash pile...

Read moreDetails

Schrödinger: The Cost Machine That Learned to Cost Less

by Moe Alsumidaie
November 17, 2026
0

Schrödinger spent three decades building physics simulations so precise that major pharmaceutical companies use them to design drugs before synthesizing a single molecule. It went public in February...

Read moreDetails
Next Post

Walmart raises full-year guidance as operating income accelerates to 16 percent in Q3

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

Lilly’s Ledger: The $4.2 Billion Footnote Management Hopes You Miss

October 30, 2026

Lowe’s: The Stock Is Down a Quarter, the Business Just Grew 10%. The Gap Is the Story.

August 18, 2026

Evidence Sheet: Abbvie (ABBV)

November 4, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.